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Abstract An ENU mutagenesis screen to identify novel
epigenetic modifiers was established in mice carrying a
multi-copy GFP transgene, which is expressed in a varie-
gated manner in erythrocytes and is highly sensitive to
epigenetic silencing. The screen has produced mouse
mutants of both known modifiers of epigenetic state, such
as Dnmt1 and Smarca5, and novel modifiers, such as
Smchd1 and Rlf. Here we report two mouse lines generated
from the screen, MommeD6 and MommeD20, with point
mutations in D14Abb1e. These are the first mouse mutants
of D14Abb1e (also known as Fam208a), a gene about
which little is known. Heterozygous intercrosses show that
homozygous mutants from both the MommeD6 and Mom-
meD20 lines are not viable beyond gastrulation,
demonstrating an important role for D14Abb1e in devel-
opment. We demonstrate that haploinsufficiency for
D14Abb1e effects transgene expression at the RNA level.
Analysis of the predicted D14Abb1e protein sequence
reveals that it contains putative nuclear localisation signals
and a domain of unknown function, DUF3715. Our studies
reveal that D14Abb1e is localised to the nucleus and is
expressed in skin and testes.
Introduction
Epigenetic modifications of the DNA and the chromatin
proteins that package it play critical roles in the estab-
lishment of normal patterns of gene expression in multi-
cellular organisms (Feinberg 2007). Errors in this process
can lead to defects in development and disease (Berdasco
and Esteller 2013; Feil and Fraga 2011; Issa and Baylin
1996). To identify genes involved in the establishment and
maintenance of the epigenetic state of the genome in
mammals, our group designed an ENU (N-ethyl-N-nitro-
sourea) mutagenesis screen in mice (Blewitt et al. 2005).
The screen is based on the observation that multi-copy
transgene arrays are susceptible to silencing (Martin and
Whitelaw 1996). The FVB/NJ mouse line used in our
screen, Line3, carries a multi-copy transgene array, con-
taining a green fluorescent protein (GFP) transgene under
the control of the human alpha globin promoter and
enhancer that is expressed in a variegated manner i.e.
approximately 55 % of erythrocytes express GFP, whereas
the remaining 45 % do not because the transgene is epi-
genetically silenced (Preis et al. 2003). Alleles that varie-
gate in this way are known as metastable epialleles, and the
percentage of expressing cells is sensitive to the levels of
proteins involved in the establishment of epigenetic state
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(Rakyan et al. 2002). Wild-type male FVB/NJ mice car-
rying the GFP transgene (Line3) were injected with ENU to
induce mutations in spermatogonial stem cells, and then
mated with untreated Line3 dams. Offspring were weaned
at three weeks, at which time a drop of blood was collected
for screening via flow cytometry. Offspring which showed
a shift in the percentage of GFP-expressing cells were
selected for heritability testing, by backcrossing to un-
mutagenised, wild-type (Line3) mice. If altered GFP
expression was observed across multiple generations, the
mutant mouse line was designated as a MommeD (Modifier
of murine metastable epiallele Dominant) (Fig. 1a) (Ble-
witt et al. 2005).
To date the screen has produced around 40 MommeD
mouse lines and causative mutations have been identified
in 29 of these (Daxinger et al. 2013). The finding of several
well-studied epigenetic modifiers, such as DNA methyl-
transferases, histone modifying enzymes and chromatin
remodelers, validates the design of the screen (Ashe et al.
2008; Chong et al. 2007; Daxinger et al. 2013; Youngson
Fig. 1 MommeD6 and MommeD20 are mutant lines identified from
an ENU mutagenesis screen. a A schematic overview of the design of
the screen. Briefly, male FVB/NJ mice carrying a multi-copy GFP
transgene array (Line3), which is sensitive to epigenetic silencing,
were injected with ENU, a chemical mutagen ENU and mated with
female Line3 mice. Offspring were screened, via flow cytometry, for
changes in GFP expression using a drop of blood from the tail. Mice
carrying mutations that caused a shift in the percentage of red blood
cells expressing GFP were either (1) backcrossed to unmutagenised
Line3 mice to remove additional mutations or (2) backcrossed twice
to C57BL/6J mice carrying the transgene (Line3C) to produce
recombinant mice, which were used for linkage analysis. Causative
mutations were identified by sequencing candidate genes from the
linked interval. b Representative GFP expression profiles of wild-type
and heterozygous mutant MommeD6 and MommeD20 mice, showing
erythrocyte fluorescence (x-axis) versus the number of cells detected
at each fluorescence level (y-axis). The GFP? gate was set to exclude
99.9 % of wild-type cells, i.e. cells with no GFP transgene. Mice
shown in each graph are from a single litter, since day to day variation
in FACS readings prevents pooling of multiple litters (n = 3 mice for
each FACS profile). The profiles of wild-type and mutant mice are
shown in black and red, respectively. Data are representative of
observations from over 100 litters per line. c Table showing
representative percentage of GFP-expressing cells and mean fluores-
cence per expressing cell for MommeD6 and MommeD20
(mean ± SD). d A graph depicting Mean fluorescence versus
percentage of GFP-expressing cells for wild-type Line3 mice (blue
square) and heterozygous mice from all MommeD lines reported to
date, including MommeD6 and MommeD20 (black squares) and
MommeD7 (grey circle) mice. All other MommeD lines are shown as
grey crosses. e Real-time RT-PCR analysis of GFP mRNA from
spleens of age-matched wild-type and heterozygous MommeD20
mutants, for n = 5 mice per genotype (Color figure online)
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et al. 2013). This report focuses on two additional mouse
lines, MommeD6 and MommeD20, which we have now
found to contain mutations in D14Abb1e (DNA segment,
Chr 14, Abbott 1 expressed). MommeD6 and MommeD20
are the first mouse mutants to be described for D14Abb1e.
Materials and methods
Mouse lines
The ENU mutagenesis screen was conducted as described
previously (Blewitt et al. 2005). Line3 and Line3C mice are
homozygous for a multi-copy GFP transgene under the
control of the human alpha globin promoter and linked to
the HS-40 enhancer and are inbred on the FVB/NJ and
C57BL/6J lines, respectively. Inbred FVB/NJ and C57BL/
6J mice were originally purchased from ARC Perth (Perth,
WA, Australia). MommeD6 and MommeD20 mice used in
this study were backcrossed to unmutagenised Line3 for at
least five generations to remove additional ENU mutations
from the genome. Sperm from MommeD6 and MommeD20
mutant mouse lines has been cryopreserved and is available
via the Australian Phenome Facility (http://apf.anu.edu.au).
All animal work was approved by the QIMR Berghofer
Animal Ethics Committee.
Flow cytometry
Mice were weaned at three weeks of age and a drop of
blood was collected into a tube of Osmosol buffer (Lab
Aids Pty Ltd., Narrabeen, NSW, Australia). Samples were
analysed on a FACScan (Becton Dickinson, Franklin Lake,
NJ, USA). A Gate was set so as to demarcate GFP-
expressing cells, such that 99.9 % of wild-type erythro-
cytes were excluded. Prior to identification of the causative
mutation, mice were classified as phenotypic wild-types or
phenotypic mutants on the basis of their FACS profile.
Linkage analysis
Mutants were backcrossed to Line3C for two generations to
generate C57BL/6J/FVB/NJ N2 recombinants. PCR primers
were used to amplify regions containing either microsatellite
or single nucleotide polymorphisms (SNPs) which differed
between C57BL/6J and FVB/NJ strains. SNP markers were
chosen which result in the creation or destruction of a
restriction enzyme digest site. PCR products were resolved
on agarose gels. Within the linked interval wild-type mice
will display a C57BL/6J/C57BL/6J genotype, whereas
mutant mice will be C57BL/6J/FVB/NJ. Linked interval
coordinates refer to the NCBI37/mm9 genome assembly.
Primer sequences are available on request.
Genotyping
Mouse tissue (either a 0.5 cm piece of tail or embryo tissue)
was digested with tail lysis buffer containing 1 mg/mL Pro-
teinase K (Astral Scientific, Australia) overnight at 55 C.
Samples were heated to 95 C for 5 mins to inactivate Pro-
teinase K. PCRs of an interval containing the mutation were
performed with the following primers MommeD6: For-
GGCCTTTGGTCAGAAAACCT Rev-GTTAAAATATG
TTACTGATGATGGCTCA; MommeD20: For- GCCTT
TTAGGCGGAGTTTTC Rev- GAAACGCTTCAAACCT
GAGC. Genotypes of MommeD20 samples were determined
by Sanger sequencing, using Big Dye 3.1 (Applied Biosys-
tems, Foster City, CA). MommeD6 samples were genotyped
either by Sanger sequencing or restriction enzyme digest using
AciI (New England Biolabs, Beverly, MA). The MommeD6
mutation results in the creation of an AciI site.
Cell culture and siRNA
HeLa cells were maintained in complete media i.e. DMEM
supplemented with 10 % foetal calf serum and penicillin/
streptomycin. All culture reagents were purchased from
Life Technologies (Gaithersburg, MD). For siRNA trans-
fection experiments, cells were plated in complete media
24 h before transfection. Immediately prior to transfection,
media were changed to DMEM only. Cells were transfec-
ted with Lipofectamine 2000 (Life Technologies, Gai-
thersburg, MD) according to the manufacturers’
instructions. Serum was added after 4 h to give a final
concentration of 10 %. Cells were harvested after 36 hrs
for Western blotting. The following siRNAs were obtained
from Qiagen: All Stars Negative Control, Hs_C3orf63_7:
GAGGAACTTAGTACTCCAGAA and Hs_C3orf63_4:
TTCCGAGTTCATATATTCTAA
Real-time RT-PCR and splice site analysis
RNA was extracted using Trizol (Life Technologies, Gai-
thersburg, MD) according to the manufacturer’s instructions.
cDNA was prepared using 1st strand cDNA synthesis kit
(Life Technologies, Gaithersburg, MD). Real-time PCR was
performed on a Rotor-Gene 6000 (Corbett Research, Mort-
lake, NSW, Australia) using Sybr Green (Life Technologies,
Gaithersburg, MD). Primers: GFP For: CTACCCCGACC
ACATGAAGC and GFP Rev: CTTGTAGTTGCGTC
GTCCT. All values were normalised to the house-keeping
gene b-actin (b-actin For: CCAGAGCAAGAGAGGTATC
and b-actin Rev: GACCAGAGGCATACAGGGAC). For
splice site analysis a forward primer from exon 1 and a
reverse primer from exon 4 were used to amplify cDNA from
both wild-type and MommeD20 mutants. Products were
separated on an agarose gel and individual bands were
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excised from the gel and purified using a gel extraction kit
(Qiagen) according to the manufacturer’s instructions. Pro-
ducts were sequenced as described above.
Western blotting
Protein lysates were prepared using an 8 M urea buffer and
quantified using a BCA assay (Thermo Fisher Scientific,
Waltham, MA), according to the manufacturer’s instruc-
tions. Lysates were separated on pre-cast TGX gels (Bio-Rad
Laboratories, Richmond, CA) and transferred onto Immo-
bilon PVDF membranes (Millipore, Bedford, MA). Mem-
branes were blocked for 20 mins in 5 % milk, 1 % BSA
solution in PBST before incubating overnight at 4 C with
the appropriate primary antibody. Antibodies used were anti-
FAM208A (SC99819, Santa Cruz Biotechnology, Santa
Cruz, CA), anti-FAM208A (HPA017142, Sigma-Aldrich, St
Louis, MO), anti-GAPDH (Cell Signaling Technology,
Beverly, MA), anti-Smarca5 (Abcam, Cambridge, UK) and
anti-c-tubulin (Sigma-Aldrich, St Louis, MO). The follow-
ing day, membranes were washed with PBST, incubated with
the appropriate secondary antibody at room temperature for
1 hour (Dako Corp, Carpinteria, CA) and then washed again
with PBST. Membranes were developed using ECL (Bio-
Rad Laboratories, Richmond, CA) and images captured
using a digital chemiluminescent detection system (DNR
Bio-Imaging Systems Ltd, Jerusalem, Israel).
Histology
Embedding and sectioning of tissue, and H&E staining of
sections was performed by the QIMR Berghofer Histology
Service. Slides were scanned using an Aperio slide scanner
(Aperio Technology, Vista, CA).
Statistical analyses
Statistical significance of quantitative data was determined
by two-tailed Student’s t test. The proportions of genotypes
were compared to expected Mendelian ratios using a v2
test. For all datasets a minimum of three biological repli-
cates were analysed.
Results
MommeD6 and MommeD20 showed an increase
in the percentage of red blood cells expressing the GFP
transgene and higher mean fluorescence per expressing
cell
In our initial description of the screen we reported the
FACS profiles for the first six mutants identified from the
screen, including MommeD6 (Blewitt et al. 2005). Mom-
meD6?/- mice showed an increase in the percentage of red
blood cells expressing GFP compared to wild-type litter-
mates. We also noted that MommeD6?/- displayed a
higher mean fluorescence level per expressing cell than the
three other mutant lines with an increased percentage of
GFP-expressing cells. Since then we have expanded the
screen and we now report a new mutant line, MommeD20,
which displays a similar shift in both the percentage of
GFP-expressing cells and mean fluorescence per express-
ing cell (Fig. 1c). Representative FACS profiles for both
MommeD6 and MommeD20 are shown in Fig. 1b. Graph-
ing the percentage of GFP-expressing cells vs mean fluo-
rescence for all MommeD lines revealed that MommeD6?/-
and MommeD20?/- had markedly higher mean fluores-
cence per expressing cell, relative to the observed increase
in the percent of cells expressing GFP, than other lines
identified in the screen (Fig. 1d). A third line, MommeD7,
also displayed high mean fluorescence, as was previously
noted (Ashe et al. 2008). Analysis of MommeD7?/- blood
samples revealed a high reticulocyte count and a mutation
was subsequently identified in the canonical polyadenyla-
tion signal of the haemoglobin, beta major gene (Brown
et al. 2013). Full blood count analysis and reticulocyte
counts of MommeD6?/- mice showed no differences from
wild-type littermates (data not shown). We determined the
level of GFP mRNA in MommeD20?/- spleen using real-
time RT-PCR. Significantly higher levels of GFP mRNA
were observed in MommeD20?/- mice compared to wild-
types (Fig. 1e).
MommeD6 and MommeD20 contain mutations
in D14Abb1e
To determine the causative mutations, each line was
backcrossed twice to C57BL/6J mice carrying the GFP
transgene (Line3C), to produce NF2 recombinant mice.
These recombinants were used to map the location of the
causative mutation using traditional SNP and microsatellite
markers. MommeD6 mapped to a 2.5 Mbp interval on
Chromosome 14 between the markers rs13482101
(26,285,297 bp) and rs6396829 (28,814,048 bp) (Fig. 2a).
An overlapping linked interval was identified in Mom-
meD20 (Chromosome 14: 22–31 Mbp). This interval fits
with all of the phenotypic wild-type mice analysed (57/57)
and all but one of the phenotypic mutant mice analysed
(69/70). All but one exon, including exon/intron junctions
and splice sites, were sequenced for seven genes from the
interval including; the homeobox genes Cphx1 (cytoplas-
mic polyadenylated homeobox 1), Duxbl1 (double
homeobox B-like 1) and Hesx1 (homeobox gene expressed
in ES cells), SNORA71D and SNORA67 which encode
untranslated, small nucleolar RNAs (snoRNAs), Appl1
296 S. K. Harten et al.: First mouse mutants of D14Abb1e
123
(adaptor protein, phosphotyrosine interaction, PH domain
and leucine zipper containing 1), which has links to the
nucleosomal remodelling and histone deacetylase (NuRD)
complex (Banach-Orlowska et al. 2009; Feng and Zhang
2003; Miaczynska et al. 2004) and D14Abb1e (Chambers
and Abbott 1996). A single mutation was identified in exon
Fig. 2 MommeD6 and MommeD20 contain mutations in D14Abb1e.
a Mapping interval for MommeD6 and MommeD20 mice. MommeD6
and MommeD20 mutants were produced in the FVB/NJ strain and
backcrossed to C57BL/6J mice to produce recombinant mice. The results
for markers used around the linked interval are shown. Left margin,
markers used; right margin, marker positions on mouse chromosome 14
(NCBI Build 37, August 2008). Filled boxes represent markers
homozygous for the C57BL/6J allele; open boxes represent markers
heterozygous for FVB/NJ and C57BL/6J. Data represent defining
recombinant events, with the number of mice identified with each
genotype below. An interval of 2.5 Mb was defined for MommeD6,
between rs13482101 and rs6396829. An interval of 9 Mb was defined for
MommeD20, between D14Mit50 and D14Mit14. b Representative DNA
sequence electropherograms for wild-type, MommeD6 and MommeD20
mutant mice. In both MommeD6 and MommeD20, a single base pair
mutation was detected in D14Abb1e (MommeD6 Exon 2, T ? C;
MommeD20 Intron 1, T ? C). c cDNA analysis of the exon 1–exon2
region of D14Abb1e in wild-type and MommeD20 mutant mice. Red
arrows show location of primer sites used to amplify cDNA from wild-
type and D14Abb1eMommeD20/? mice. Amplified products are shown on a
representative image of an agarose gel. Schematic diagrams show
splicing of D14Abb1e, based on Sanger sequencing of bands detected on
gel. The T ? C point mutation found in MommeD20 mice, shown in red,
occurs within the slice donor site of intron 1. Sequencing of the
*1,500 bp band, detected only in mutant samples, showed partial
incorporation intron 1, including a predicted premature stop codon
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2 of D14Abb1e, a T to C mutation, encoding a non-con-
servative amino acid change (L130P) at a highly conserved
leucine residue (Fig. 2b). We have designated this mutant
allele as D14Abb1eMommeD6.
Candidate gene sequencing of D14Abb1e in MommeD20
mutant mice revealed a T to C mutation at the canonical
splice site exon1/intron1 (Fig. 2B). Analysis of cDNA
prepared from wild-type and MommeD20 heterozygous
mutants was performed using primers designed to amplify
across intron 1 of D14Abb1e. Wild-type cDNA produced a
single PCR product of the expected size; however, a sec-
ond, higher molecular weight product was also detected in
MommeD20 heterozygous samples. Sanger sequencing of
the bands showed that splicing of the mutant allele was
altered, resulting in the incorporation of additional 1,160
nucleotides. Translation of the abnormal mRNA species is
predicted to result in the incorporation of 79 amino acids,
of no substantial homology to any known protein, followed
by a premature stop codon, which would elicit nonsense-
mediated decay (Fig. 2c). We have designated this allele as
D14Abb1eMommeD20.
Almost nothing is known about D14Abb1e and, to our
knowledge, MommeD6 and MommeD20 are the first
reported mouse mutants. D14Abb1e shows evolutionary
conservation within vertebrates. FAM208A, the human
homologue of D14Abb1e, shows 82 % conservation.
Analysis of the D14Abb1e amino acid sequence predicts a
single predicted domain of unknown function (DUF3715)
(Punta et al. 2012). Identification of D14Abb1e mutations
in two independent mutant lines, MommeD6 and Mom-
meD20, provides strong support that these are the causative
mutations.
D14Abb1e protein is expressed in skin and testis
FAM208A is predicted to encode three protein variants in
humans, with molecular weights of 140, 171 and 182 kDa
(Artimo et al. 2012). In contrast, mouse D14Abb1e is
predicted to encode a single isoform of 169 kDa (Artimo
et al. 2012). To determine the ability of available anti-
bodies to detect FAM208A, we treated HeLa cells with
either a control siRNA or two independent siRNAs tar-
geting FAM208A. Western blotting of control-treated cells
revealed two bands, which were detected with two inde-
pendent anti-FAM208A antibodies. The higher molecular
weight band, whose size is consistent with the larger pre-
dicted isoforms of FAM208A, was reduced upon siRNA
treatment; however, levels of the lower molecular weight
band were unchanged (Fig. 3a). Both FAM208A siRNAs
target a region common to the transcripts of all predicted
FAM208A protein-coding variants. Additional non-coding
FAM208A transcripts are predicted. Therefore, the band at
150 kDa may represent either a non-specific band or
FAM208A variant not present in current prediction dat-
abases and not targeted by the siRNAs.
Next, we asked in which tissues D14Abb1e is most
highly expressed by blotting a panel of protein lysates
prepared from adult mouse tissues. Using an anti-
D14Abb1e designed against a peptide from the C-terminal
region of D14Abb1e (HPA017142) we observed strong
signals in skin, brain and testis (Fig. 3b). Signals at the
same molecular weights were observed in skin and testis
samples blotted with a second anti-D14Abb1e antibody,
(sc99819), designed against an independent epitope in the
C-terminus of D14Abb1e, however no band was observed
in brain lysates (Fig. 3b). Previous studies have detected
D14Abb1e transcript in the brain (Chambers and Abbott
1996), but these findings suggest that further studies are
needed to clarify the level of protein expression in this
tissue (see ‘Discussion’). The D14Abb1e transcript pro-
duced by the MommeD20 mutant allele is predicted to
result in the incorporation of an early stop codon. To test
the effect of the MommeD20 allele on D14Abb1e protein
expression we asked whether the signal was reduced in
lysates from D14Abb1eMommeD20/? compared to wild-type
mice. Western blots of testis lysates revealed less
D14Abb1e in D14Abb1eMommeD20/? lysates compared to
wild-types, as expected (Fig. 3c).
D14Abb1e is localised to the nucleus
Analysis of the primary amino acid sequence of FAM208A
and D14Abb1e revealed the presence of monopartite and
bipartite putative nuclear localisation signals that are con-
served between species (Fig. 4a). Total, cytoplasmic and
nuclear fractions were prepared from both human cell line
(HeLa) and mouse testis and tested for the presence of the
protein by Western analysis. In each case the protein was
found to be localised in the nucleus (Fig. 4b, c and data not
shown).
D14Abb1e is critical for normal development
MommeD6 and MommeD20 heterozygous intercrosses
were established to examine viability of D14Abb1e mutant
mice. Genotyping of offspring revealed that both inter-
crosses failed to produce any viable homozygous mutant
offspring at three weeks of age (Fig. 5a). These results are
consistent with our previous report of MommeD6 inter-
crosses, prior to identification of the underlying mutation,
in which we found no phenotypic homozygous offspring at
weaning on the basis of FACS profiles (Blewitt et al.
2005). In each case approximately double the number of
heterozygous offspring were observed compared to wild-
types (MommeD6 intercross: 102 wild-types and 182 het-
erozygotes; MommeD20 intercross: 21 wild-types and 50
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heterozygotes), suggesting that both the MommeD6 and
Mommed20 alleles are semi-dominant and homozygous
lethal. D14Abb1eMommeD6/? mice were also crossed to
D14Abb1eMommeD20/? mice to test for genetic comple-
mentation. No compound heterozygous animals,
D14Abb1eMommeD6/MommeD20, out of 79 offspring, were
observed at three weeks of age, as expected.
Timed matings of MommeD6 and MommeD20 inter-
crosses were performed to determine the stage of devel-
opment at which D14Abb1e homozygous mutants fail.
Characterisation of the MommeD6 line, prior to the iden-
tification of the causative mutation, revealed arrest prior to
10.5 dpc (Ashe et al. 2008). Here we show that at 8.5 dpc,
a mixture of developmentally normal and developmentally
delayed embryos, were present (Fig. 5b). Empty decidua
were also observed. Where possible, embryo tissue was
collected and genotyped. Empty decidua or embryonic
tissue that failed to genotype was recorded as not deter-
mined (ND). In both lines developmentally normal
embryos were found to be wild-type or heterozygous
mutants. Homozygous MommeD6 and MommeD20
mutants showed severe developmental delay and were
present in less than expected numbers (Fig. 5b). Timed
matings of D14Abb1eMommeD6/? mice crossed to
D14Abb1eMommeD20/? mice, revealed that development of
compound heterozygotes was also impaired, showing a
similar gross morphology to MommeD6 and MommeD20
homozygotes (Fig. 5b). Representative pictures of
Fig. 3 D14Abb1e protein is most highly expressed in skin and testis.
a Representative Western blots of human (HeLa) protein lysates
treated with siRNAs targeting FAM208A. Two anti-FAM208A
antibodies which recognise independent epitopes, HPA017142 and
sc99819, were used to probe duplicate Western membranes. Both
membranes were also probed with an anti-GAPDH antibody. The
GAPDH data presented correspond to the membrane blotted with
HPA017142. b Representative Western blots showing expression of
D14Abb1e in a panel of adult mouse tissues, blotted with two
independent antibodies (HPA017142 and sc99819). c-Tubulin was
also blotted as a loading control. c Western blotting of D14Abb1e in
protein lysates from wild-type and D14Abb1eMommeD20/? testis. A
representative blot is shown. All Western analyses were performed
with at least three independent sets of biological replicates. Repre-
sentative Westerns are shown in each case
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wild-type, homozygous and compound heterozygous
mutant embryos are shown in Fig. 5c. To examine the
phenotype further, D14Abb1eMommeD20/? intercrosses were
set up and dissections carried out at 7.5 dpc. Haemotoxylin
and eosin staining was carried out on sections from 37
embryos. 28 were classified as developmentally normal and
9 were developmentally abnormal, showing failure to
gastrulate. These embryos were not genotyped. Represen-
tative pictures are shown in Fig. 5c. These findings suggest
that D14Abb1e is necessary for successful gastrulation.
Discussion
This study describes two mouse mutants produced in our
mutagenesis screen, MommeD6 and MommeD20, which
each carry a unique mutation in D14Abb1e. Identification
of D14Abb1e mutations in two independent lines provides
strong support that these are the causative mutations. These
findings are also consistent with genetic complementation
studies, which suggested disruption of a common gene or
pathway, and with FACS profile data. The mutations in
both MommeD6 (non-conservative amino acid change) and
MommeD20 (splice site mutation) are expected to disrupt
D14Abb1e function. Western blotting of lysates from
MommeD20 heterozygotes showed a reduction in
D14Abb1e protein, consistent with it acting as a null allele.
MommeD6 and MommeD20 have similar phenotypes,
suggesting that the L130P mutation also creates a null
allele.
Loss of D14Abb1e is critical for development, with
homozygous mutants unable to progress beyond gastrula-
tion. Further study is needed to uncover the molecular
function of D14Abb1e in early development. Unlike most
other mouse mutants produced from the screen, both
D14Abb1e mutant lines show a substantial shift in mean
fluorescence per expressing cell. Although the screen was
designed to detect modifiers of transgene silencing, it is
important to be aware that mutants may show a shift in
their GFP FACS profile for other reasons. For example,
mutations in genes alter the red blood cell count or affect
stability of the GFP RNA or protein (Garneau et al. 2007).
For instance, the high mean fluorescence per expressing
cell observed in MommeD7 results from a mutation in the
polyadenylation signal of the haemoglobin, beta adult
major chain gene which leads to low mean corpuscular
volume and reticulocytosis (Brown et al. 2013). Mom-
meR1, a mutant line identified from a modified screen to
Fig. 4 D14Abb1e is localised
to the nucleus. a Bioinformatic
analysis of the 1498 amino acid
sequence of D14Abb1e
performed using protein domain
prediction programs Predict
Protein, PSORTII and NLS
Mapper, indicated the presence
of multiple putative highly
conserved nuclear localisation
signals. b, c Western blots of
total, nuclear and cytoplasmic
cell fractions showing protein
localisation of FAM208A/
D14Abb1e in a human cell line
(b) or mouse testis (c). Lysates
were also blotted for Gapdh and
Smarca5, which are known to be
localised to the cytoplasm and
nucleus, respectively. Data
shown are representative of
three independent experiments
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identify recessive mutants, also displays an unusually high
mean fluorescence per expressing cell compared to shift in
the percentage of GFP expressing cells. MommeR1 was
found to have a mutation in Foxo3A (Youngson et al.
2011). At this stage it is unclear whether either Foxo3A or
D14Abb1e have a role in the establishment or maintenance
of chromatin. Up-regulation of GFP mRNA levels in
D14Abb1e mutant lines, combined with its nuclear locali-
sation, is consistent with a role for D14Abb1e in regulating
gene expression at the level of RNA, either by influencing
transcription, potentially via an epigenetic mechanism, or
via effects on post-transcriptional mechanisms of RNA
regulation, for example splicing, polyadenylation, mRNA
trafficking or mRNA decay (Di Liegro et al. 2014; Garneau
et al. 2007).
D14Abb1e was initially isolated from a mouse cDNA
library prepared from brain (Chambers and Abbott 1996);
however, little is currently known about its molecular
function. Our Western blot analysis of adult mouse tissues,
performed with an anti-D14Abb1e antibody (HPA017142;
C-terminal epitope), detected signal in skin, testes and
brain tissue lysates. Using an independent antibody
Fig. 5 D14Abb1e is critical for normal development. a Genotypes of
viable offspring from heterozygous intercrosses of D14Abb1eMommeD6/?
or D14Abb1eMommeD20/? at 3 weeks of age. The results of compound
D14Abb1eMommeD6/? 9 D14Abb1eMommeD20/? crosses is also shown.
Data show the number of mice observed (and in brackets the
percentage). The proportions of genotypes observed were compared
to expected Mendelian ratios using the v2 test. b Timed matings at 8.5
and 7.5 dpc of D14Abb1eMommeD6/? or D14Abb1eMommeD20/? hetero-
zygous intercrosses, or compound D14Abb1eMommeD6/? 9
D14Abb1eMommeD20/? crosses. Embryos from 8.5 dpc crosses were
genotyped. Data show the number of mice observed (and in brackets the
percentage). The proportions of genotypes observed, of normal
developmental stage, were compared to expected Mendelian ratios
using the v2 test. Histological examination of H&E sections was used to
classify 7.5 dpc embryos as either developmentally normal or abnor-
mal. c Representative photomicrographs of dissected embryos (8.5 and
9.5 dpc) and H&E sections from 7.5 dpc D14Abb1eMommeD20/?
heterozygous intercrosses
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(sc99819; C-terminal epitope), we confirmed that the bands
observed in skin and testes are likely to be D14Abb1e.
However, despite the observed similar molecular weights
in all three tissues, the latter antibody failed to detect
D14Abb1e in brain lysates. It is possible that the
HPA017142 antibody recognises a D14Abb1e isoform,
which is expressed in brain and does not contain the epi-
tope recognised by the sc99819 antibody. Further study is
needed to examine the expression of D14Abb1e isoforms
across different organs, both during development and in
adult tissues.
D14Abb1e has also been isolated from a yeast two-
hybrid screen as a binding partner for Retinoblastoma (Rb)
(Li et al. 2000) and found to be a direct transcriptional
target of Oct4/Sox2 in mouse embryonic stem cells using
ChIP-PCR (Campbell et al. 2007). A recent report showed
that FAM208A interacts with H3K9me3, a chromatin mark
associated with gene silencing. Several other proteins
encoded by the human homologues of genes detected in
our screen were also identified as K9me3 interactors in this
study (Eberl et al. 2013). The importance of these inter-
actions is yet to be demonstrated in vivo. Using microarray
analysis, two studies have reported that FAM208A
expression levels are decreased in colorectal adenocarci-
nomas compared to normal colorectal tissue; however, it
remains unclear whether these changes are a cause or
consequence of tumourigenesis (Kucherlapati 2012; Se-
shagiri et al. 2012). Additional experiments using mouse
mutants would be beneficial in clarifying the role of
D14Abb1e in these settings.
Conclusion
Our studies have revealed that D14Abb1e encodes a
nuclear protein, which is critical for normal development in
the mouse. The mutant mouse lines described here will be
useful in future molecular studies to uncover the mecha-
nism of action of D14Abb1e and its role in development
and disease.
Acknowledgments This study was supported by the National
Health and Medical Research Council of Australia Grants to SKH and
EW.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
Artimo P, Jonnalagedda M, Arnold K, Baratin D, Csardi G, de Castro
E, Duvaud S, Flegel V, Fortier A, Gasteiger E, Grosdidier A,
Hernandez C, Ioannidis V, Kuznetsov D, Liechti R, Moretti S,
Mostaguir K, Redaschi N, Rossier G, Xenarios I, Stockinger H
(2012) ExPASy: SIB bioinformatics resource portal. Nucleic
Acids Res 40:W597–W603
Ashe A, Morgan DK, Whitelaw NC, Bruxner TJ, Vickaryous NK,
Cox LL, Butterfield NC, Wicking C, Blewitt ME, Wilkins SJ,
Anderson GJ, Cox TC, Whitelaw E (2008) A genome-wide
screen for modifiers of transgene variegation identifies genes
with critical roles in development. Genome Biol 9:R182
Banach-Orlowska M, Pilecka I, Torun A, Pyrzynska B, Miaczynska
M (2009) Functional characterization of the interactions between
endosomal adaptor protein APPL1 and the NuRD co-repressor
complex. Biochem J 423:389–400
Berdasco M, Esteller M (2013) Genetic syndromes caused by
mutations in epigenetic genes. Hum Genet 132:359–383
Blewitt ME, Vickaryous NK, Hemley SJ, Ashe A, Bruxner TJ, Preis
JI, Arkell R, Whitelaw E (2005) An N-ethyl-N-nitrosourea
screen for genes involved in variegation in the mouse. Proc Natl
Acad Sci USA 102:7629–7634
Brown FC, Scott N, Rank G, Collinge JE, Vadolas J, Vickaryous N,
Whitelaw N, Whitelaw E, Kile BT, Jane SM, Curtis DJ (2013)
ENU mutagenesis identifies the first mouse mutants reproducing
human beta-thalassemia at the genomic level. Blood Cells Mol
Dis 50:86–92
Campbell PA, Perez-Iratxeta C, Andrade-Navarro MA, Rudnicki MA
(2007) Oct4 targets regulatory nodes to modulate stem cell
function. PLoS One 2:e553
Chambers DM, Abbott CM (1996) Isolation and mapping of novel
mouse brain cDNA clones containing trinucleotide repeats, and
demonstration of novel alleles in recombinant inbred strains.
Genome Res 6:715–723
Chong S, Vickaryous N, Ashe A, Zamudio N, Youngson N, Hemley
S, Stopka T, Skoultchi A, Matthews J, Scott HS, de Kretser D,
O’Bryan M, Blewitt M, Whitelaw E (2007) Modifiers of
epigenetic reprogramming show paternal effects in the mouse.
Nat Genet 39:614–622
Daxinger L, Harten SK, Oey H, Epp T, Isbel L, Huang E, Whitelaw
N, Apedaile A, Sorolla A, Yong J, Bharti V, Sutton J, Ashe A,
Pang Z, Wallace N, Gerhardt DJ, Blewitt ME, Jeddeloh JA,
Whitelaw E (2013) An ENU mutagenesis screen identifies novel
and known genes involved in epigenetic processes in the mouse.
Genome Biol 14:R96
Di Liegro CM, Schiera G, Di Liegro I (2014) Regulation of mRNA
transport, localization and translation in the nervous system of
mammals (Review). Int J Mol Med 33:747–762
Eberl HC, Spruijt CG, Kelstrup CD, Vermeulen M, Mann M (2013) A
map of general and specialized chromatin readers in mouse
tissues generated by label-free interaction proteomics. Mol Cell
49:368–378
Feil R, Fraga MF (2011) Epigenetics and the environment: emerging
patterns and implications. Nat Rev Genet 13:97–109
Feinberg AP (2007) Phenotypic plasticity and the epigenetics of
human disease. Nature 447:433–440
Feng Q, Zhang Y (2003) The NuRD complex: linking histone
modification to nucleosome remodeling. Curr Top Microbiol
Immunol 274:269–290
Garneau NL, Wilusz J, Wilusz CJ (2007) The highways and byways
of mRNA decay. Nat Rev Mol Cell Biol 8:113–126
Issa JP, Baylin SB (1996) Epigenetics and human disease. Nat Med
2:281–282
Kucherlapati R (2012) Comprehensive molecular characterization of
human colon and rectal cancer. Nature 487:330–337
Li Q, Wen H, Ao S (2000) Identification and cloning of the cDNA of
a Rb-associated protein RAP140a. Sci China C 43:637–647
Martin DI, Whitelaw E (1996) The vagaries of variegating transgenes.
Bioessays 18:919–923
302 S. K. Harten et al.: First mouse mutants of D14Abb1e
123
Miaczynska M, Christoforidis S, Giner A, Shevchenko A, Uttenwe-
iler-Joseph S, Habermann B, Wilm M, Parton RG, Zerial M
(2004) APPL proteins link Rab5 to nuclear signal transduction
via an endosomal compartment. Cell 116:445–456
Preis JI, Downes M, Oates NA, Rasko JE, Whitelaw E (2003)
Sensitive flow cytometric analysis reveals a novel type of parent-
of-origin effect in the mouse genome. Curr Biol 13:955–959
Punta M, Coggill PC, Eberhardt RY, Mistry J, Tate J, Boursnell C,
Pang N, Forslund K, Ceric G, Clements J, Heger A, Holm L,
Sonnhammer EL, Eddy SR, Bateman A, Finn RD (2012) The
Pfam protein families database. Nucleic Acids Res 40:D290–
D301
Rakyan VK, Blewitt ME, Druker R, Preis JI, Whitelaw E (2002)
Metastable epialleles in mammals. Trends Genet 18:348–351
Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE,
Conboy CB, Chaudhuri S, Guan Y, Janakiraman V, Jaiswal BS,
Guillory J, Ha C, Dijkgraaf GJ, Stinson J, Gnad F, Huntley MA,
Degenhardt JD, Haverty PM, Bourgon R, Wang W, Koeppen H,
Gentleman R, Starr TK, Zhang Z, Largaespada DA, Wu TD, de
Sauvage FJ (2012) Recurrent R-spondin fusions in colon cancer.
Nature 488:660–664
Youngson NA, Vickaryous N, van der Horst A, Epp T, Harten S,
Fleming JS, Khanna KK, de Kretser DM, Whitelaw E (2011) A
missense mutation in the transcription factor Foxo3a causes
teratomas and oocyte abnormalities in mice. Mamm Genome
22:235–248
Youngson NA, Epp T, Roberts AR, Daxinger L, Ashe A, Huang E,
Lester KL, Harten SK, Kay GF, Cox T, Matthews JM, Chong S,
Whitelaw E (2013) No evidence for cumulative effects in a
Dnmt3b hypomorph across multiple generations. Mamm Gen-
ome 24:206–217
S. K. Harten et al.: First mouse mutants of D14Abb1e 303
123
